Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma

JAMA - Journal of the American Medical Association

Volumn 323, Issue 16, 2020, Pages 1582-1589

  Shen, Chenguang ^a   Wang, Zhaoqin ^a   Zhao, Fang ^a   Yang, Yang ^a   Li, Jinxiu ^a   Yuan, Jing ^a   Wang, Fuxiang ^a   Li, Delin ^a,b   Yang, Minghui ^a   Xing, Li ^a   Wei, Jinli ^a   Xiao, Haixia ^a,b   Yang, Yan ^a   Qu, Jiuxin ^a   Qing, Ling ^a   Chen, Li ^a   Xu, Zhixiang ^a   Peng, Ling ^a   Li, Yanjie ^a   Zheng, Haixia ^a   Chen, Feng ^a   Huang, Kun ^a   Jiang, Yujing ^a   Liu, Dongjing ^a   Zhang, Zheng ^a   Liu, Yingxia ^a   Liu, Lei ^a   more..

^a SHENZHEN THIRD PEOPLE S HOSPITAL   (China)

^b Chinese Academy of Sciences   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA1 INTERFERON; ARBIDOL; DARUNAVIR; FAVIPIRAVIR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LOPINAVIR PLUS RITONAVIR; METHYLPREDNISOLONE; NEUTRALIZING ANTIBODY; OXYGEN; ANTIVIRUS AGENT; GLUCOCORTICOID; VIRUS ANTIBODY;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; ARTIFICIAL VENTILATION; BLOOD OXYGEN TENSION; BODY TEMPERATURE; CHINA; CLINICAL ARTICLE; CONVALESCENCE; CORONAVIRUS DISEASE 2019; CRITICALLY ILL PATIENT; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACORPOREAL OXYGENATION; FEMALE; FOLLOW UP; HOSPITAL DISCHARGE; HUMAN; LENGTH OF STAY; MALE; MIDDLE AGED; PLASMA TRANSFUSION; PRIORITY JOURNAL; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; TREATMENT OUTCOME; VENTILATOR WEANING; VIRUS LOAD; VIRUS PNEUMONIA; BETACORONAVIRUS; BLOOD; BLOOD DONOR; CASE REPORT; CORONAVIRUS INFECTION; CRITICAL ILLNESS; IMMUNOLOGY; ORGAN DYSFUNCTION SCORE; PANDEMIC; PASSIVE IMMUNIZATION; PATHOPHYSIOLOGY;

ADULT; AGED; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; BETACORONAVIRUS; BLOOD DONORS; CORONAVIRUS INFECTIONS; CRITICAL ILLNESS; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; METHYLPREDNISOLONE; MIDDLE AGED; ORGAN DYSFUNCTION SCORES; PANDEMICS; PNEUMONIA, VIRAL; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 85082418248     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2020.4783     Document Type: Article

References (23)

1. Huang C, Wang Y, Li X, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395 (10223): 497-506. 31986264
2. WHO. Novel coronavirus (COVID-19) situation. Updated March 24, 2020. https://experience.arcgis.com/experience/685d0ace521648f8a5beeeee1b9125cd
3. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020. Published online February 24, 2020. doi: 10.1001/jama.2020.2648 32091533
4. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020; 14 (1): 69-71. 31996494
5. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;
6. Kraft CS, Hewlett AL, Koepsell S,; Nebraska Biocontainment Unit and the Emory Serious Communicable Diseases Unit. The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States. Clin Infect Dis. 2015; 61 (4): 496-502. 25904375
7. van Griensven J, Edwards T, de Lamballerie X,; Ebola-Tx Consortium. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med. 2016; 374 (1): 33-42. 26735992
8. Florescu DF, Kalil AC, Hewlett AL, Administration of brincidofovir and convalescent plasma in a patient with Ebola virus disease. Clin Infect Dis. 2015; 61 (6): 969-973. 25991468
9. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med. 2007; 357 (14): 1450-1451. 17914053
10. Hung IF, To KK, Lee CK, Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011; 52 (4): 447-456. 21248066
11. Burnouf T, Radosevich M. Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med J. 2003; 9 (4): 309. 12904626
12. Cheng Y, Wong R, Soo YO, Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005; 24 (1): 44-46. 15616839
13. Yang Y, Yang M, Shen C, Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections. Preprint. medRxiv. Preprint posted online February 17, 2020. doi: 10.1101/2020.02.11.20021493
14. Villar J, Blanco J, del Campo R,; Spanish Initiative for Epidemiology, Stratification & Therapies for ARDS (SIESTA) Network. Assessment of PaO/FiO for stratification of patients with moderate and severe acute respiratory distress syndrome. BMJ Open. 2015; 5 (3):
15. Liu C, Yang Y, Gao Y, Viral architecture of SARS-CoV-2 with post-fusion spike revealed by Cryo-EM. bioRxiv. Preprint posted online March 5, 2020. doi: 10.1101/2020.03.02.972927
16. Yeh KM, Chiueh TS, Siu LK, Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother. 2005; 56 (5): 919-922. 16183666
17. Mair-Jenkins J, Saavedra-Campos M, Baillie JK,; Convalescent Plasma Study Group. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015; 211 (1): 80-90. 25030060
18. Ng KT, Oong XY, Lim SH, Viral load and sequence analysis reveal the symptom severity, diversity, and transmission clusters of rhinovirus infections. Clin Infect Dis. 2018; 67 (2): 261-268. 29385423
19. de Jong MD, Simmons CP, Thanh TT, Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med. 2006; 12 (10): 1203-1207. 16964257
20. Shen C, Chen J, Li R, A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses. Sci Transl Med. 2017; 9 (412):
21. Shen C, Zhang M, Chen Y, An IgM antibody targeting the receptor binding site of influenza B blocks viral infection with great breadth and potency. Theranostics. 2019; 9 (1): 210-231. 30662563
22. Wang C, Li W, Drabek D, A human monoclonal antibody blocking SARS-CoV-2 infection. bioRxiv. Preprint posted online March 12, 2020. doi: 10.1101/2020.03.11.987958
23. Lu CL, Murakowski DK, Bournazos S, Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science. 2016; 352 (6288): 1001-1004. 27199430